AbbVie's (ABBV) Allergan Aesthetics unit said Wednesday the US Food and Drug Administration approved its Juvederm Volux XC injectable gel to improve...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
AbbVie's (ABBV) neutral rating at Goldman Sachs was maintained despite Q2 sales of plaque psoriasis drug Skyrizi significantly outperforming the firm's...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
| Address | 1 North Waukegan Road North Chicago, Illinois 60064-6400 |
| Phone | +1.847.932.7900 |
| Number of Employees | 30,000 |
| Recent SEC Filing | 08/04/2022 10-Q |
| Chairman & Chief Executive Officer | Richard A. Gonzalez |
| Vice Chairman & President | Robert A. Michael |
| Chief Financial Officer & Senior Vice President | Scott T. Reents |
| Chief Scientific Officer, Senior VP-R&D | Thomas J. Hudson |
| Price Open | $138.04 |
| Previous Close | $138.04 |
| 52 Week Range | $105.56 - 175.91 |
| Market Capitalization | $246.1 B |
| Shares Outstanding | 1.8 B |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major |
| Current Dividend / Yield | $1.41 / 4.09% |
| Dividend Ex-Date | 07/14/2022 |
| Dividend Pay-Date | 08/15/2022 |
| Dividend Yield 5 Year Average | 4.08% | Next Earnings Announcement | 11/04/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 19.80 |
| Earnings per Share | $6.90 |
| Beta vs. S&P 500 | N/A |
| Revenue | $32.8 B |
| Net Profit Margin | 22.18% |
| Return on Equity | 87.05% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
